|
Form Serial Number: |
IS20180619E00352
|
1.
Date of relevant event: |
13/06/2018 (dd/mm/yyyy)
|
2.
Date when the substantial shareholder becomes aware of the relevant event / interest in the shares (if later): |
(dd/mm/yyyy)
|
3.
Stock code: |
01548 |
4.
Name of listed corporation: |
Genscript Biotech Corporation |
5.
Class of shares: |
Ordinary Shares |
6.
Number of issued shares in class: |
1,833,285,795 |
7.
Name of substantial shareholder (English) as printed on HKID Card/Passport: |
(Surname) |
JIN |
(Other names) |
WEIHONG |
|
|
|
10.
Name of substantial shareholder (Chinese): |
金伟红 |
11.
Chinese Character Code as printed on HKID Card: |
|
|
14.
Details of relevant event: |
|
Brief description of relevant event |
Capacity in which shares were/are held |
Number of shares bought/sold or involved |
Currency of transaction |
On Exchange |
Off Exchange |
Before relevant event |
After relevant event |
Highest price (per share) |
Average price (per share) |
Average consideration (per share) |
Nature of consideration |
Long position |
1111 | The percentage level of your interest in the shares has increased because: new shares were issued to you after you have reduced your interest in shares by placing them to placee(s) under a top-up placing | |
|
|
75,000,000 |
HKD |
|
|
26.5000 |
|
Short position |
|
|
|
|
|
|
|
|
|
|
|
15.
Total shares immediately before the relevant event: |
| Total number of shares | Percentage figure (%) |
Long position | 995,955,561 | 54.32 |
|
|
16.
Total shares immediately after the relevant event: |
| Total number of shares | Percentage figure (%) |
Long position | 995,955,561 | 54.32 |
|
|
17.
Capacity in which interests disclosed in Box 16 are held: |
Capacity code | Number of shares |
2201 | Interest of corporation controlled by you |
| |
2401 | A concert party to an agreement to buy shares described in s.317(1)(a) |
| |
| |
|
|
18.
Further information in respect of derivative interests: |
Derivatives code | Number of shares |
| |
|
|
19.
Further information in relation to interests of children under 18 and/or spouse: |
Child/Spouse | Name of child/spouse | Number of shares |
Spouse | Zhang Fangliang | |
|
|
20.
Further information in relation to interests of corporations controlled by substantial shareholder: |
Name of controlled corporation | Address and place of incorporation | Name of controlling shareholder | % control | Direct interest (Y/N) | Number of shares |
Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Zhang Fangliang | 28.83 | Y | |
Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Wang Luquan | 23.68 | Y | |
Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Wang Ye | 6.02 | Y | |
Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Zhang Fangliang | 12.04 | Y | |
Genscript Corporation | Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA | Wang Ye | 6.02 | Y | |
|
|
21.
Further information in relation to interests held by substantial shareholder jointly with another person: |
Name of joint shareholder | Address | Number of shares |
| | |
|
|
22.
Further information from a trustee, a beneficiary of a trust, or a person who has set up a discretionary trust: |
Names of trust | Address | Status code | Number of shares |
2017 FANG LIANG ZHANG TRUST | Addresses of individuals are not displayed. | | |
|
|
23.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
Names of other parties | Address | Number of shares |
| | |
Total number of shares in which a substantial shareholder is interested under sections 317 and 318 | |
|
|
24.
Supplementary information: |
As disclosed in the announcement of Genscript Biotech Corporation (the "Company") dated 5 June 2018, 8 June 2018 and 13 June 2018, a shareholder entered into the placing and subscription agreement dated 5 June 2018, pursuant to which the Company allotted and issued to such shareholder an aggregate of 75,000,000 ordinary shares of the Company.
|
25.
Log/Serial Number of the previous form: |
|
26.
Number of concert party document(s) under section 317 attached/uploaded: |
|
Date of filing this Form 1: |
19/06/2018 (dd/mm/yyyy)
|
|